Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 551 - 600 out of 123,770

Document Document Title
WO/2017/031325A1
The present disclosure relates to oxadiazine compounds, pharmaceutical compositions comprising an effective amount of an oxadiazine compound and methods for using an oxadiazine compound in the treatment of a neurodegenerative disease, co...  
WO/2017/030115A1
The present invention provides a compound that has inhibiting activity against mPGES-1 and is useful in the prevention or treatment of pain, rheumatoid arthritis, osteoarthritis, fever, Alzheimer's disease, multiple sclerosis, arterioscl...  
WO/2017/029820A1
The present invention relates to: a radioactive halogen-labeled pyrido[1,2-a]benzimidazole derivative compound represented by a specific general formula or a salt thereof; or a radioactive medicine comprising the compound or the salt.  
WO/2017/031427A1
Compounds having activity as mTOR inhibitors are disclosed. The compounds have the following structure (I) including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, and A are as defined here...  
WO/2017/031319A1
Aspects of the disclosure relate to methods for treating disorders using agents for promoting hypoglossal motoneuron excitability. In some instances the disorders include obstructive sleep apnea (OSA), cataplexy, attention deficit/hypera...  
WO/2017/028708A1
The present invention discloses a recombinant lipoprotein modified by monosialotetrahexosylganglioside, an application in preparing a drug carrier thereof, and an application in preparing a drug treating or preventing a disease associate...  
WO/2017/029567A1
A Transdermal Drug Delivery System (TDDS) of the reservoir or plaster type for administrating clobazam for the treatment of various types of anxiety and epilepsy, for 1 day, 2 day, 3 day, 4 day, 5 day, 6 day and/or 7- day continuous appl...  
WO/2017/030973A1
Provided herein are self-delivering oligonucleotides that are characterized by efficient RISC entry, minimum immune response and off-target effects, efficient cellular uptake without formulation, and efficient and specific tissue distrib...  
WO/2017/025565A1
Compounds of the Formula (I) are provided which compounds are inhibitors of BACE1.  
WO/2017/027345A1
The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt thereof.  
WO/2017/025491A1
The present invention provides a compound of formula I, having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the pres...  
WO/2017/027136A3
The present invention provides a cannabis-based flavonoid pharmaceutical composition including any one or more selected from the group of Apigenin, Cannflavin A, Cannflavin B, Cannflavin C, Chrysoeriol, Cosmosiin, Flavocannabiside, Kaemp...  
WO/2017/027685A3
The present invention relates to antibody-based molecules (including single domain antibody fragment, scFv molecules, antibodies, antibody fragments, diabodies, and the epitope-binding domains thereof) that are capable of immunospecifica...  
WO/2017/025868A1
A compound of Formula (I) is provided: or pharmaceutically acceptable enantiomers, salts or solvates thereof. The invention further relates to the use of the compounds of Formula (I) as TD02 inhibitors. The invention also relates to the ...  
WO/2017/025532A1
The present invention is directed to the combined use of BACE1 inhibitor of Formula (I) and a compound useful in active or passive Tau immunotherapy, a compound useful in active or passive Aβ peptide immunotherapy, an NMDA receptor anta...  
WO/2017/027848A1
Glycosylated peptides with giycosylation at or near the C-terminal domain of the peptide have an enhanced ability to cross the blood brain barrier (BBB) and/or enhanced half-lives. These glycosylated peptides may be used as drugs. For ex...  
WO/2017/025058A1
Provided are substituted indole compounds and their using methods and uses. In particular, disclosed are indole compounds for 5-hydroxytryptamine reuptake inhibition and/or 5-HT1A receptor agonists, and their pharmaceutical compositions....  
WO/2017/026516A1
The present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof or a solvate of these. The present invention provides a compound having Nrf2 activation ability.  
WO/2017/025695A1
The invention concerns the compounds of formula (l) in which W, X, Y, Z and Het are as defined in the description. The compounds of formula (I) are modulators of the NURR1 receptor.  
WO/2017/027848A8
Glycosylated peptides with glycosylation at or near the C-terminal domain of the peptide have an enhanced ability to cross the blood brain barrier (BBB) and/or enhanced half-lives. These glycosylated peptides may be used as drugs. For ex...  
WO/2017/025912A1
The present invention discloses compositions of liquid and gel formulation containing aripiprazole in the form of a patch for transdermal delivery wherein the aripiprazole is present in the amount of 7% w/v, the gel contains a gelling ag...  
WO/2017/025559A1
The present invention provides compounds of Formula (I) for the treatment of neurodegenerative or cognitive diseases. The method further provides for piperidine-2-one and piperidine-2-thione intermediates to compounds of formula (I).  
WO/2017/021881A1
Use of 2-(5S-Methyl-2-oxo-4R-phenyl-pyrrolidin-1-yl)-acetamide or its pharmaceutically acceptable salt in manufacture of a medicament for prophylaxis and treatment of seizure.  
WO/2017/023739A1
The present invention provides compounds of formula I which are capable of inhibition of the activation of hNav1.1 or hNavl.6 sodium channels in neurons. Pharmaceutical compositions comprising these compounds are also provided. Methods f...  
WO/2017/021384A1
The present invention relates to compounds of formula (I) wherein R1 is hydrogen, F or CI; L is a bond or lower alkylene; R2 is -(CH2)nO-lower alkyl, lower alkyl substituted by halogen, -(CH2)nC(0)0-lower alkyl, phenyl substituted by low...  
WO/2017/021730A1
This invention relates to compounds that are agonists of the muscarinic receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions conta...  
WO/2017/021728A9
This invention relates to compounds that are agonists of the muscarinic M4 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions co...  
WO/2017/021729A1
This invention relates to compounds that are agonists of the muscarinic M1 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions co...  
WO/2017/022768A1
[Problem] To obtain a β-nicotinamide mononucleotide (β-NMN)-containing solid yeast extract from a safe yeast which has been eaten over a long time. To obtain a β-NMN composition derived from a yeast. [Solution] It was found that a β-...  
WO/2017/021686A1
An amyloidogenic peptide biospecific agent comprises a nanoparticle which is visible under near infrared (NIR) and/or using Magnetic Resonance Imaging (MRI) and/or Computed Tomography (CT). The biospecific agent further comprises at leas...  
WO/2017/024129A1
The invention provides a method for treating a medical condition in a patient, the method comprising: administering to a patient in need (hereof a pharmaceutical composition comprising a therapeutically effective amount of (i) a first th...  
WO/2017/024180A1
The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A7, and each of Ra, Rb, R1, R2, R3, R8 R9 a...  
WO/2017/021728A1
This invention relates to compounds that are agonists of the muscarinic M4 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions co...  
WO/2017/022648A1
Provided is a novel compound, which selectively and strongly inhibits JAK3, has an excellent effect of inhibiting the proliferation of human peripheral blood monocytes and a high oral absorbability and shows an activity of inhibiting IL-...  
WO/2017/020783A1
Provided is an application of bacteroides fragilis in prevention and/or treatment of meningitis, in particular, an application of the bacteroides fragilis in preparation of medicines, pharmaceutical compositions, food, health care produc...  
WO/2017/023941A1
Disclosed are novel benzazole compounds and compositions comprising the compounds of the formula. The compounds are useful as kinase inhibitors including interleukin receptor associated kinases (IRAK) inhibitors. Also disclosed are metho...  
WO/2017/024255A1
The invention relates to compositions of nicotinamide mononucleotide derivatives and their methods of use. The invention also relates to methods of preparing nicotinamide mononucleotide derivatives. The invention relates to pharmaceutica...  
WO/2017/024018A1
Provided are novel compounds of Formula I: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORy. Also provided are pharmaceutical...  
WO/2017/021305A1
The present invention relates to a composition of less than or equal to about 1% of pheromones useful to treat or prevent a behavioral stress problem of a non-human mammal. It also relates to a device comprising said composition and to a...  
WO/2017/023724A1
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides encoding AADC for the treatment, prophylaxis, palliation or amelioration of diseases, conditions and/or symptoms re...  
WO/2017/023833A1
The present invention is directed to combination pharmacological treatments that induce a prolonged, modest decrease in core body temperature, to the range of ~95°F to ~98.5°F (~35°C to ~36.7°C) to mitigate and delay the early onset ...  
WO/2017/021438A1
The present invention relates to a selected amide of γ-hydroxybutyric acid, a process of manufacture and uses thereof. The invention also includes a pharmaceutical composition comprising an effective amount of the selected compound of t...  
WO/2017/021920A1
The disclosure provides compounds having formula (I), wherein the substituents are as defined herein. The compounds are useful for modulating the dopamine D3 receptor and for treating conditions associated therewith, such as addictions, ...  
WO/2017/021304A1
The present invention provides a pharmaceutical dosage form comprising oxycodone and naloxone (or pharmaceutically acceptable salts thereof) for use in the treatment of Bladder Pain Syndrome (BPS) and/or at least one, preferably at least...  
WO/2017/021963A1
A method of treating cancer in a subject is disclosed. The method comprises administering to the subject: (i) a therapeutically effective amount of an inhibitory agent that down-regulates an amount of a polypeptide selected from the grou...  
WO/2017/023361A1
The present application relates to a method of treating migraine or cluster headache in a human patient, said method comprising administering subcutaneously composition comprising sumatriptan or its pharmaceutically acceptable salt, in a...  
WO/2017/021319A1
The present invention deals with novel compounds which are reactivators of human acetylcholinesterase, pharmaceutical compositions comprising said compounds, and their use in the treatment of a nervous and/or respiratory failure due to i...  
WO/2017/021951A1
Provided are compositions which include N-methyl-d-aspartate receptor (NMDA-R) antagonists. Moreover, provided are methods for reducing the permeability of the blood- brain-barrier, in a patient, by administering to the patient, a compos...  
WO/2017/017363A1
The invention relates to a gaseous drug including xenon gas for use in treating impaired cholinergic synaptic transmission in humans. Impaired cholinergic synaptic transmission causes disease of the central nervous system of said humans,...  
WO/2017/018475A1
The present invention provides a preventive or therapeutic agent for diseases such as mood disorders, anxiety disorders, schizophrenia, autism spectrum disorders, and Alzheimer's disease, which involve group II metabotropic glutamate (mG...  

Matches 551 - 600 out of 123,770